Patents Assigned to Actinium Pharmaceuticals, Inc.
  • Patent number: 8715598
    Abstract: The invention is directed to a method for the purification of Radium, in particular 226Ra, for target preparation for an essentially pure 225Ac production from available radioactive sources, using an extraction chromatography in order to separate chemically similar elements such as Ba, Sr, and Pb from the desired Ra; wherein said extraction chromatography has an extractant system on the basis of a crown ether. The invention is related to a method for recycling of 226Ra, for target preparation for 225Ac production from radium sources irradiated with accelerated protons (p,2n), after separation of the produced 225Ac. In this method a combination of the above extraction chromatography and a cation exchange chromatography is used. The obtained 226Ra is essentially free of the following chemical contaminants consisting of Ag, Al, As, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Sr, V, Zn, and Ba.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: May 6, 2014
    Assignee: Actinium Pharmaceuticals Inc.
    Inventors: Eva Kabai, Josue M. Moreno Bermudez, Richard Henkelmann, Andreas Türler
  • Patent number: 8349391
    Abstract: The present invention refers to a method for producing a radium target for the production of radionuclides by means of accelerated protons, whereby at least one radium containing material out of an aqueous-organic solution or suspension of such a material is applied by means of a dispersing device on a surface in such a way that the dispersing device and the surface are moving relatively towards each other and that the solvent is removed substantially spontaneously. Further, the invention refers to a radium target that is created in such a way that it may exhibit an activity of up to 1.5 curie. The radium targets according to the present invention serve for the production of the radionuclide 225Ac, which may be used in nuclear medicine in the treatment of cancer, particularly in form of its daughter nuclide 213Bi.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: January 8, 2013
    Assignee: Actinium Pharmaceuticals Inc.
    Inventors: Mark Harfensteller, Ernst Huenges, Michael Schilp, Josue Manuel Moreno Bermudez
  • Publication number: 20120251415
    Abstract: The invention is directed to a method for the purification of Radium, in particular 226Ra, for target preparation for an essentially pure 225Ac production from available radioactive sources, using an extraction chromatography in order to separate chemically similar elements such as Ba, Sr, and Pb from the desired Ra; wherein said extraction chromatography has an extractant system on the basis of a crown ether. The invention is related to a method for recycling of 226Ra, for target preparation for 225Ac production from radium sources irradiated with accelerated protons (p,2n), after separation of the produced 225Ac. In this method a combination of the above extraction chromatography and a cation exchange chromatography is used. The obtained 226Ra is essentially free of the following chemical contaminants consisting of Ag, Al, As, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Sr, V, Zn, and Ba.
    Type: Application
    Filed: April 6, 2012
    Publication date: October 4, 2012
    Applicant: Actinium Pharmaceuticals Inc.
    Inventors: Eva KABAI, Josue M. MORENO BERMUDEZ, Richard HENKELMANN, Andreas Türler
  • Publication number: 20120220754
    Abstract: Methods for generating an Ac-225 radioconjugate comprising a monoclonal antibody (mAb) (IgG) is disclosed. The Ac-225 radioimmunoconjugate is an [Ac-225]-p-SCN-Bn-DOT AIHuM195 radioimmunoconjugate.
    Type: Application
    Filed: July 22, 2010
    Publication date: August 30, 2012
    Applicant: Actinium Pharmaceuticals Inc.
    Inventors: Jaime Simon, A. Gaylord King, Josue Manuel Moreno Bermudez
  • Patent number: 8153087
    Abstract: The present application is directed to a method for the purification of Radium, in particular 226Ra, for target preparation for an essentially pure 225Ac production from available radioactive sources, using an extraction chromatography in order to separate chemically similar elements such as Ba, Sr, and Pb from the desired Ra; wherein said extraction chromatography has an extractant system on the basis of a crown ether. The invention is further related to a method for recycling of 226Ra, for target preparation for 225Ac production from radium sources irradiated with accelerated protons (p,2n), after separation of the produced 225AC. In this method a combination of the above extraction chromatography and a cation exchange chromatography is used. The obtained 226Ra is essentially free of the following chemical contaminants consisting of Ag, Al, As, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Sr, V, Zn, and Ba.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: April 10, 2012
    Assignee: Actinium Pharmaceuticals Inc.
    Inventors: Eva Kabai, Josue Manuel Moreno Bermudez, Richard Henkelmann, Andreas Turler
  • Publication number: 20100104489
    Abstract: The present application is directed to a method for the purification of Radium, in particular 226Ra, for target preparation for an essentially pure 225Ac production from available radioactive sources, using an extraction chromatography in order to separate chemically similar elements such as Ba, Sr, and Pb from the desired Ra; wherein said extraction chromatography has an extractant system on the basis of a crown ether. The invention is further related to a method for recycling of 226Ra, for target preparation for 225Ac production from radium sources irradiated with accelerated protons (p,2n), after separation of the produced 225AC. In this method a combination of the above extraction chromatography and a cation exchange chromatography is used. The obtained 226Ra is essentially free of the following chemical contaminants consisting of Ag, Al, As, Be, Bi, Ca, Cd, Co, Cr, Cu, Fe, Ga, K, Li, Mg, Mn, Na, Ni, Pb, Sr, V, Zn, and Ba.
    Type: Application
    Filed: March 5, 2009
    Publication date: April 29, 2010
    Applicant: Actinium Pharmaceuticals Inc.
    Inventors: Eva Kabai, Josue M. Moreno Bermudez, Richard Henklemann, Andreas Turler
  • Publication number: 20090191122
    Abstract: The present invention describes a method for purification of 225Ac from irradiated 226Ra-targets provided on a support, comprising a leaching treatment of the 226Ra-targets for leaching essentially the entirety of 225Ac and 226Ra with nitric or hydrochloric acid, followed by a first extraction chromatography for separating 225Ac from 226Ra and other Ra-isotopes and a second extraction chromatography for separating 225Ac from 210Po and 210Pb. The finally purified 225Ac can be used to prepare compositions useful for pharmaceutical purposes.
    Type: Application
    Filed: February 19, 2007
    Publication date: July 30, 2009
    Applicant: ACTINIUM PHARMACEUTICALS INC.
    Inventors: Josue Manuel Moreno Bermudez, Andreas Turler, Richard Henklemann, Eva Kabai, Ernst Huenges
  • Publication number: 20080279772
    Abstract: The present invention relates to the field of site directed therapy. More specifically the invention relates to site directed radio therapy, and provides a method for production of radioconjugates and an apparatus for radioimmunotherapy. The method, conjugates and apparatus can be practicalized without the need for radioactive shielding and/or airtight facilities. Without these restrictions the invention provides a simple and efficient means of therapy at the bed-side of the patient.
    Type: Application
    Filed: May 9, 2008
    Publication date: November 13, 2008
    Applicant: ACTINIUM PHARMACEUTICALS INC.
    Inventor: Maurits W. GEERLINGS
  • Patent number: 7374936
    Abstract: The present invention relates to the field of site directed therapy. More specifically the invention relates to site directed radio therapy, and provides a method for production of radioconjugates and an apparatus for radioimmunotherapy. The method, conjugates and apparatus can be practicalized without the need for radioactive shielding and/or airtight facilities. Without these restrictions the invention provides a simple and efficient means of therapy at the bed-side of the patient.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: May 20, 2008
    Assignee: Actinium Pharmaceuticals, Inc.
    Inventor: Maurits W Geerlings
  • Publication number: 20070153954
    Abstract: The present invention refers to a method for producing a radium target for the production of radionuclides by means of accelerated protons, whereby at least one radium containing material out of an aqueous-organic solution or suspension of such a material is applied by means of a dispersing device on a surface in such a way that the dispersing device and the surface are moving relatively towards each other and that the solvent is removed substantially spontaneously. Further, the invention refers to a radium target that is created in such a way that it may exhibit an activity of up to 1.5 curie. The radium targets according to the present invention serve for the production of the radionuclide 225Ac, which may be used in nuclear medicine in the treatment of cancer, particularly in form of its daughter nuclide 213Bi.
    Type: Application
    Filed: October 30, 2006
    Publication date: July 5, 2007
    Applicant: Actinium Pharmaceuticals, Inc.
    Inventors: Mark Harfensteller, Ernst Huenges, Michael Schilp, Josue Bermudez
  • Publication number: 20070076834
    Abstract: The present invention relates to a radium target as well as to a method for producing it for the production of radionuclides by means of accelerated protons, wherein an electrodeposition of radium out of at least one aqueous organic solution containing 226Ra ions is carried out on at least one aluminium surface, wherein the aluminium surface is connected as cathode. With the 226Ra target according to the present invention, 225Ac/213Bi, which can be used, for example, for radioimmunotherapy for cancer treatment, can be produced continuously and in sufficient quantities at a reasonable price.
    Type: Application
    Filed: April 11, 2006
    Publication date: April 5, 2007
    Applicant: Actinium Pharmaceuticals Inc.
    Inventors: Josue Moreno Bermudez, Andreas Turler, Richard Henklemann, Mark Harfensteller, Ernst Huenges, Michael Schilp, Oliver Buck, Mauritius Geerlings